Gonane Estradiol Valerate Gonane Estradiol Valerate

X
[{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Launches Estradiol Valerate Injection, USP","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3004

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Estradiol Valerate Injection USP is indicated (i) in the treatment of vasomotor symptoms associated with menopause (ii) in the management of hormonal imbalances due to castration or primary ovarian failure (iii) in the treatment of androgen-dependent carcinoma of the prostate.

            Lead Product(s): Estradiol Valerate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Close
            4
            Post Enquiry
            POST ENQUIRY